Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

26.03.22	Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies (PR Newswire)
24.03.22	Eli Lilly: FDA Issues CRL For BLA For Sintilimab; Unable To Approve Application In Its Current Form (RTTNews)
24.03.22	Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer (PR Newswire)
18.03.22	Statement of changes in beneficial ownership of securities (RSS)
17.03.22	Form 4 59478 (RSS)
16.03.22	Eli Lilly: EMPA-KIDNEY Trial Shows Efficacy For Jardiance At Early Stage; Trial To Stop (RTTNews)
16.03.22	Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease (PR Newswire)
14.03.22	Boeing : Arajet Orders 20 737 MAX Aircraft (RTTNews)
08.03.22	Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) (PR Newswire)
07.03.22	Form 4 59478 (RSS)
03.03.22	Lilly to Participate in Barclays Global Healthcare Conference (PR Newswire)
01.03.22	Eli Lilly Says Jardiance Provides Significant Benefit In Adults Following Acute Heart Failure (RTTNews)
01.03.22	Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial (PR Newswire)
28.02.22	Lilly to Participate in Cowen Health Care Conference (PR Newswire)
28.02.22	Biotech Stocks Facing FDA Decision In March 2022 (RTTNews)
25.02.22	FDA Approves Jardiance To Treat Adults With Heart Failure (RTTNews)
24.02.22	US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction (PR Newswire)
24.02.22	Form 4 59478 (RSS)
22.02.22	Lilly Launches Institute For Genetic Medicine; Invests $700 Mln (RTTNews)
22.02.22	Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site (PR Newswire)
18.02.22	Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study (PR Newswire)
16.02.22	Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence (PR Newswire)
11.02.22	FDA Issues Emergency Use Authorization For Eli Lilly's Covid-19 Treatment (RTTNews)
11.02.22	Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (PR Newswire)
11.02.22	FDA Panel Votes Against Lilly's Lung Cancer Drug For China-only Trial (RTTNews)
11.02.22	Form 4 59478 (RSS)
11.02.22	Lilly Reaches Deal With U.S. To Supply Up To 600,000 Doses Of Bebtelovimab For COVID-19 Treatment (RTTNews)
10.02.22	Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (PR Newswire)
10.02.22	Form SC 13G 59478 (RSS)
03.02.22	Eli Lilly Q4 Results Top Estimates; Reaffirms FY22 Outlook (RTTNews)
03.02.22	Eli Lilly And Co. Profit Declines In Q4 (RTTNews)
03.02.22	Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients (PR Newswire)
02.02.22	UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents (PR Newswire)
01.02.22	Lilly to Participate in Guggenheim Oncology Conference (PR Newswire)
29.01.22	Eli Lilly To Invest $1 Bln To Build New Plant In Concord (RTTNews)
28.01.22	Lilly announces $1 billion investment in new manufacturing facility in North Carolina (PR Newswire)
28.01.22	Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts (RTTNews)
28.01.22	Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis (PR Newswire)
20.01.22	Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement (PR Newswire)
20.01.22	Form 4 59478 (RSS)
18.01.22	Evotec Enters Research Partnership With Lilly - Quick Facts (RTTNews)
06.01.22	Lilly to Participate in the J.P. Morgan Healthcare Conference (PR Newswire)
06.01.22	Lilly Buys Exclusive Rights Of Entos' Fusogenix Nucleic Acid Technology (RTTNews)
06.01.22	Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications (PR Newswire)
28.12.21	Form 4 59478 (RSS)
24.12.21	Innovent Biologics : China Accepts SNDA Of TYVYT On Lung-cancer (RTTNews)
21.12.21	Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals (RTTNews)
21.12.21	Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study (PR Newswire)
17.12.21	Form 4 59478 (RSS)
15.12.21	Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer

22:34

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone

17:56

Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an

16:06

Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa